Status:
COMPLETED
Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Conditions:
Bipolar Disorder I
Eligibility:
All Genders
Brief Summary
To investigate the safety for an observation period of 52 weeks with use of Abilify prolonged release aqueous suspension for intramuscular (IM) injection in patients with bipolar I disorder for preven...
Eligibility Criteria
Inclusion
- \-
Exclusion
- patients with a known hypersensitivity to aripiprazole
Key Trial Info
Start Date :
April 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 21 2024
Estimated Enrollment :
535 Patients enrolled
Trial Details
Trial ID
NCT04812379
Start Date
April 7 2021
End Date
June 21 2024
Last Update
March 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pharmacovigilance Department
Osaka, Osaka, Japan, 540-0021